Shares of Atossa Genetics Inc (NASDAQ:ATOS) reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $1.40 and last traded at $1.44, with a volume of 100 shares changing hands. The stock had previously closed at $1.46.
ATOS has been the subject of several recent research reports. Maxim Group reissued a “$2.47” rating and set a $10.00 price target on shares of Atossa Genetics in a report on Wednesday, July 18th. ValuEngine raised Atossa Genetics from a “hold” rating to a “buy” rating in a report on Wednesday, July 4th.
Atossa Genetics (NASDAQ:ATOS) last released its quarterly earnings results on Monday, August 13th. The company reported ($2.90) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($2.53). Equities analysts expect that Atossa Genetics Inc will post -4.08 earnings per share for the current fiscal year.
Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.
Featured Story: Hedge Funds Explained
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.